Company
x.ilio Therapeutics
We envision a brighter future for people living with cancer, where immuno-oncology therapies eliminate cancer at its source without severe systemic side effects.
Also known as Xilio, Xilio Therapeutics, Xilio Therapeutics, Inc.
- Business model
- B2B
- Legal name
- Xilio Therapeutics, Inc.
- xiliotx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
Funding snapshot
- Total raised
- $145MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $95M2021-02-23
Funding rounds
- Round, 2021
- $95M2021-02-23, SEC form D sold, 17 investors
- Round, 2021
- $50.2M2021-01-20, SEC form D sold, 16 investors
Loading relationship preview